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Abstract
An accurate, simple, sensitive and selective reversed phase liquid chromatographic method has been developed for the
determination of ebastine in its pharmaceutical preparations. The proposed method depends on the complexation
ability of the studied drug with Zn
2+ ions. Reversed phase chromatography was conducted using an ODS C18 (150 ×
4.6 mm id) stainless steel column at ambient temperature with UV-detection at 260 nm. A mobile phase containing
0.025%w/v Zn
2+ in a mixture of (acetonitril/methanol; 1/4) and Britton Robinson buffer (65:35, v/v) adjusted to pH 4.2,
has been used for the determination of ebastine at a flow rate of 1 ml/min. The calibration curve was rectilinear over
the concentration range of 0.3 - 6.0 μg/ml with a detection limit (LOD) of 0.13 μg/ml, and quantification limit (LOQ) of
0.26 μg/ml. The proposed method was successfully applied for the analysis of ebastine in its dosage forms, the
obtained results were favorably compared with those obtained by a comparison method. Furthermore, content
uniformity testing of the studied pharmaceutical formulations was also conducted. The composition of the complex as
well as its stability constant was also investigated. Moreover, the proposed method was found to be a stability
indicating one and was utilized to investigate the kinetics of alkaline and ultraviolet induced degradation of the drug.
The first-order rate constant and half life of the degradation products were calculated.
Background
Ebastine; (4’-tert.-butyl-4-[4-(diphenylmethoxy)- piperi-
dino]butyrophenone (Figure 1), is a potent and selective
histamine H1-receptor antagonist in vivo, which has lit-
tle anticholinergic and antiserotoninergic properties [1].
This agent also has no effects on cardiovascular and
psychomotor functions, which occurred during treat-
ment with classical antihistamine agents such as chlor-
pheniramine and diphenhydramine [1]. Literature survey
reveals that the drug was determined by spectrofluori-
metry [2], and by high performance liquid chromatogra-
phy either alone in its dosage forms [3,4] or in presence
of its metabolites [5,6].
Derivatization is considered as an important tool for
analysis, especially using chromatography, and great
strides have been made in developing key reactions for
several classes of compounds since it enhances analyte
recovery, improves separation, detectability and com-
pound identification [7].
Several liquid chromatographic techniques applying
metal complex derivatizaion has been reported for the
determination of many compounds of pharmaceutical
interest such as dithiocarbamates [8], halogenated 8-
hydroxyquinolines [9], glycosaminoglycans [10], b-lac-
tams [11] and various secondary amino drugs (sympato-
mimetic, b-blocking, anti-arrythmic agents) [12].
The aim of the present work is to develop an efficient
novel liquid chromatographic method for the determina-
tion of ebastine after its complexation with Zn
2+ in a
short chromatographic run, and to prove the stability-
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© 2011 Ibrahim et alindicating property of the method, and its advantage
over the previously reported HPLC methods [3,4] in
terms of its high sensitivity. Moreover, the method illus-
trates a full detailed study for the kinetic degradation of
the drug applying the proposed method, where different
kinetic parameters have been calculated.
Experimental
Materials and reagents
￿ Ebastine (EBS); of purity 99.94% was kindly provided
by Meivo Pharmaceutical Company, Cairo, Egypt.
￿ Britton Robinson buffer was prepared [13] by mixing
0.03 M of each of acetic acid, o-phosphoric acid and
boric acid. The pH was adjusted using 0.2 M sodium
hydroxide.
￿ Methanol (Sigma-Aldrich), HPLC grade
￿ Acetonitrile (Sigma-Aldrich), HPLC grade.
￿ Sodium hydroxide (2M solution), hydrochloric acid
(2M solution), hydrogen peroxide (6% v/v solution);
(BDH, Poole, UK).
￿ Acetate buffer (pH 3.5 - 5.6) and borate buffers (pH
6 - 9) were prepared according to the British Pharmaco-
poeia [14].
￿ Zinc (II) chloride (BDH, Poole, UK), 1 × 10
-3M aqu-
eous solution, were prepared in distilled water.
Pharmaceutical preparations
* Bastab
® tablets (BN#112038), labeled to contain 20 mg
ebastine/tablet, Meivo Pharmaceutical Company, Cairo,
Egypt.
*E v a s t i n e
® syrup (BN# 94634), labeled to contain 5
mg ebastine/5 ml, Marcyrl Pharmaceutical Industries, El
Obour City, Egypt.
*E b a s t e l
® tablets (BN# 916201), labeled to contain 10
mg ebastine/tablet, Global Napi Pharmaeuticals, Cairo,
Egypt.
All were obtained from commercial sources in the
local market.
Apparatus
￿ Separation was performed with a Shimadzu C-R6A
Chromatopac equipped with a Rheodyne injector valve
with a 20 μL loop and a UV/VIS detector.
￿ A Shimadzu UV 1601 PC Spectrophotometer
equipped with a pair of 1 cm matched cells, recording
range: 0-2; wavelength: 200-400 nm; factor:1; number of
cells:1; cycle time:0.1 min was used.
￿ Mass spectroscopy was performed on DI Analysis
Shimadzu QP-2010 Plus.
￿ Infra red spectroscopy was conducted using Mattson
5000 FITR Spectrometer.
￿ TLC aluminium sheets 20 × 20 silica gel 60 F254 for
TLC were used.
Columns and mobile phases
Separation was achieved ona nE Cn u c l e o s i lC 1 8 - S N :
4115568 column (150 mm × 4.6 mm id (5 mm) com-
b i n e dw i t hag u a r dc o l u m n( M e r c k ,D a r m s t a d t ,G e r -
many). The columns were operated at ambient
temperature. The analytical system was washed daily
with 60 ml of 1:1 mixtures of water and methanol to
eliminate the mobile phase; this did not cause any
change in the column performance. The mobile phase
was prepared by mixing (acetonitrile/methanol; 1/4)
with 0.03 M Britton Robinson buffer in a ratio of 65:35
v/v at pH of 4.2. The mixture was then sonicated for 30
minutes. The resulting mobile phase was filtered
through a 0.45 μm membrane filter (Millipore, Ireland).
Standard solutions
A stock solution containing 10.0 mg/ml of EBS was pre-
pared in methanol and further diluted with the same
solvent to obtain the working concentration range for
the spectrophotometric measurements, and diluted with
the mobile phase for the HPLC measurements. This
solution was found to be stable for at least two weeks
when kept in the refrigerator.
A stock solution containing 1.0 mg/ml of cetirizine
hydrochloride internal standard was prepared in metha-
nol and further diluted with the mobile phase to obtain
a final concentration of 15.0 μg/ml.
Calibration curve
Aliquots of EBS working standard solution (20 μg/ml) cov-
ering the concentration range (0.3-6.0 μg/ml) were trans-
ferred into a series of 10 ml volumetric flasks, 2.5 ml of
acetate buffer pH 5 were added, followed by 1.5 ml of 1 ×
10
-3 MZ n C l 2, mixed with 15 μg/ml aliquots of cetirizine
hydrochloride and diluted with the mobile phase to the
mark. Twenty μL aliquots were injected (in triplicates) and
eluted with the mobile phase under the reported chroma-
tographic conditions. The calibration curve was con-
structed by plotting the peak area ratio against the final
concentration of the drug (μg/ml). Alternatively, the corre-
sponding regression equation was derived.
Analysis of tablets
Twenty tablets were weighed and pulverized. An accu-
rately weighed quantity of the powder equivalent to 20
O
N
O
Figure 1 Structural formula of ebastine.
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Page 2 of 14mg of EBS was transferred into a small conical flask,
and extracted three successive times each with 30 ml of
methanol. The extract was filtered into 100 ml volu-
metric flask. The conical flask was washed with few
millilitres of methanol and completed to the mark with
t h es a m es o l v e n t .T h ep r ocedure was followed as
described under “Calibration Curve”. The nominal con-
tents of the tablets were calculated using either the cali-
bration graph or the corresponding regression equation.
Preparation of the degradation products
For the kinetic study, 1 ml aliquots of EBS standard
solution were transferred into a series of 25 ml volu-
metric flasks to obtain a final concentration of 400 μg/
ml where 2 M sodium hydroxide, 2 M hydrochloric
acid, or 6% hydrogen peroxide were added to prepare
the alkaline, acidic, or oxidative degradation products
respectively. The solutions were left in a thermostatically
controlled water bath at different temperature settings
for a fixed time interval (15 minutes). Regarding the UV
degradation, a methanolic solution of the studied drug
was exposed to Deuterium lamp in a cabinet distance of
15 cm at room temperature, and aliquots of the hydro-
lyzed solutions were analyzed every 3 hours interval.
Aliquot volumes of the degraded solutions were trans-
ferred to a series of 10 ml volumetric flasks and neutra-
lized with 2 M hydrochloric acid, or 2 M sodium
hydroxide for alkaline and acidic degradation respec-
tively, and the steps were completed as described under
“calibration curve”. The absorption spectra were
recorded at 260 nm, log a/a-x versus time (minutes) was
plotted to get the reaction rate constant and the half life
time t1/2.
For HPLC measurements, the above solutions were
completed to the volume with the mobile phase, and
the material was tested for degradation by the apparent
decrease in the peak area ratio of the formed complex
which appears at 5.3 minute.
Isolation of the formed complex
The formed complex was successively isolated and puri-
fied by preparative TLC using methylenechloride:
methanol (90:10 v/v). The solvent was removed by eva-
poration under reduced pressure, and the purity of the
complex was tested by TLC. The TLC was performed
using chloroform: methanol (75:25 v/v) as a developing
solvent, where the Rf of ebastine and EBS-Zn
2+ complex
were 0.74 and 0.55 respectively, which in turn confirms
the completeness of the complex formation reaction.
After confirmation of the purity of the complex, infra
red (IR) and mass spectroscopy (MS) were performed to
elucidate the structure of the resultant product.
The IR spectrum of the studied complex shows the
same bands of the main functional groups in ebastine;
such as the stretching band of the C-N of the tertiary
amine at 1361 cm
-1, the stretching band corresponding
to C = O at 1677 cm
-1, and also the ether C-O band at
1072 cm
-1 (Figure 2), which means that the aforemen-
tioned functional groups were not altered through the
complexation reaction.
The MS spectrum of the complex (Figure 3) shows
the molecular ion peak at m/z 1070, and putting in con-
sideration that the molecular weight of ebastine is 470
[15]; the resultant spectrum confirms the reaction stoi-
chiometry that two moles of EBS reacts with one mole
of Zn
2+. The molecular ion peak in turn is subjected to
further fragmentation in the MS through breakage of
the bonds formed between Zn
2+ and each of the ether
oxygen and the nitrogen atom of the tertiary amino
group to yield a peak at m/z of 470; while the fragments
appearing at m/z 161 and 678 suggest fragmentation at
the carbonyl atom (Scheme 1).Scheme 1
fragmentation pattern of EBS-Zn2+ complex in the
MS.
According to this interpretation, the reaction pathway
was proposed to proceed as shown in scheme 2.
Scheme 2
pathway of complex formation reaction between EBS
and Zn2+ using the proposed method.
Validation of the method
The method was tested for linearity, sensitivity, accu-
racy, precision and robustness.
Linearity
The linearity of an analytical procedure is its ability
(within a given range) to obtain test results which are
directly proportional to the concentration of analyte in
the sample [16]. Linearity of the proposed method was
assessed by estimating the linear dependence of the
obtained peak area ratios on the concentration of EBS.
Sensitivity
Detection limit (LOD) is the lowest concentration of the
drug that can be detected, but not necessarily quanti-
tated, under the stated experimental conditions. The
limit of detection is generally quoted as the concentra-
tion yielding a signal-to-noise ratio of 3:1 [17] and is
confirmed by analyzing a number of samples near this
value using the following equation:
The signal - to - noise ratio s = H/h
Where H = height of the spectrum corresponding to
the drug
h = absolute value of the largest noise fluctuation
from the baseline of the spectrum of a blank solution.
While the limit of quantification (LOQ); is the lowest
concentration of the analyte that can be determined
with acceptable precision and accuracy. It is quoted as
the concentration yielding a signal-to-noise ratio of 10:
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near this value [17].
Accuracy
The accuracy of an analytical procedure expresses the
closeness of agreement between an accepted reference
value and the value found [16]. The accuracy of the pro-
posed method was evaluated by analyzing standard
solutions of EBS. The results obtained by the proposed
method were favorably compared with those obtained
by the comparison method [4].
Precision
The precision of an analytical procedure expresses the
closeness of agreement between a series of measure-
ments obtained from multiple sampling of the same
Figure 2 IR spectrum of EBS - Zn
2+ complex
Figure 3 MS spectrum of EBS - Zn
2+ complex
Ibrahim et al. Chemistry Central Journal 2011, 5:24
http://journal.chemistrycentral.com/content/5/1/24
Page 4 of 14homogeneous sample under the prescribed conditions.
Precision may be considered through repeatability and
intermediate precision [16].
Repeatability
Repeatability expresses the precision under the same
operating conditions over a short interval of time.
Repeatability is also termed intra-assay precision [16].
The repeatability was evaluated through the replicate
analysis of different concentrations of EBS samples,
either in pure or in dosage forms.
Intermediate precision
Intermediate precision expresses within-laboratories var-
iations: different days, different analysts, different equip-
ment, etc. [16]. It was performed through replicate
analysis of different concentrations of EBS samples,
either in pure or dosage form on four successive days.
Robustness of the method
The robustness of an analytical procedure is a measure
of its capacity to remain unaffected by small, but
deliberate variations in method parameters and provides
an indication of its reliability during normal usage [16].
The robustness of the adopted method was demon-
strated by the consistency of the values of the peak area
ratios with the deliberately minor changes in the experi-
mental parameters such as, Britton Robinson buffer of
pH 4-4.5 and (0.015 M - 0.05 M) molar strength, and
organic phase: buffer ratio (65:35-70:30) v/v which did
not greatly affect the peak area ratios.
Results and discussion
Ebastine is a weakly absorbing drug having a molar
absorptivity of 9.4 × 10
2 L. mole
-1cm
-1 .I nt h ep r e -
sent study, EBS was found to form a highly stable com-
plex with zinc (II); the complex was found to be formed
instantaneously in the presence of acetate buffer of pH
5 and has molar absorptivity of 7.6 × 10
4 L. mole
-1cm
-1 . The absorption spectrum of the complex showed a
maximum absorbance at 260 nm (Figure 4).
Separation of the formed complex (Figure 5) was
achieved using a mobile phase consisting of a mixture
of (acetonitrile/methanol; 1/4) and 0.03 M Britton
ABS
nm
Smooth: 19 Deri.: 0
200 210 220 230 240 250 260 270 280 290 300 310 320 330 340 350
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
a  
b  
Figure 4 Absorption spectra of: a) Ebastine alone (4 μg/ml) in acetate buffer pH 5 b) Ebastine- Zn (ΙΙ) complex (4 μg/ml) in acetate buffer pH 5
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pH 4.2. The mobile phase was chosen after several trials
with various proportions of the buffer and the organic
phase at different pH values. Under the described chro-
matographic conditions complete base line separation
with satisfactory resolution between the peaks was
achieved in a short chromatographic run; less than 6
minutes. The proposed method was assessed for selec-
tivity, linearity, precision, accuracy, and stability.
The different experimental parameters affecting the
separation selectivity of the liquid chromatographic sys-
tem have been investigated and optimized. Hence, the
method was applied to the determination of EBS in its
tablets, and further for content uniformity testing.
Optimization of the reaction conditions
The spectral properties of the formed complex as well
as the different experimental parameters affecting its
development and stability were carefully studied and
optimized; such factors were changed individually while
the others were kept constant. After which a detailed
study for choosing the composition of the mobile phase
was carried out for the optimum separation of the resul-
tant complex.
Optimization of the reaction conditions required for
complex formation
The effect of addition order on the absorbance value of
the system was studied. The results showed that the
addition order of EBS -acetate buffer - metal was the
best regarding absorbance intensity reading.
Using different types of buffers such as phosphate or
citrate having the same pH values selected for the pro-
posed method gave the same results; however, acetate
buffer was chosen throughout the study since no inter-
ference in the results was noticed as in the case of other
buffers. The influence of pH on the absorbance value of
the formed complex was investigated over the pH range
3.5 - 5.6 using acetate buffer and from 6 - 9 using
borate buffers. Maximum and constant absorbance value
was achieved at pH (4.5-5.5) using 2.5 ml of acetate buf-
fer. Therefore, acetate buffer of pH 5 was used.
The effect of volume of acetate buffer of pH 5 was
also studied keeping the concentrations of the drug and
the metal constant. It was found that increasing the
volume of acetate buffer (pH 5) resulted in a subsequent
increase in the absorbance value of the formed complex
up to 2 ml, after which the absorbance remained con-
stant. Therefore 2.5 ± 0.5 ml of acetate buffer of pH 5
was chosen as the optimum volume of the buffer
throughout this approach.
It was found that increasing the volume of Zn (ІІ)( 1×
10
-3 M) resulted in a gradual increase in the absorbance
value of the complex up to 1 ml, after which it remained
constant, therefore , 1.5 ± 0.5 ml of (1 × 10
-3 M) was
chosen.
The reaction was carried out at different temperature
settings (room temperature, 40, 60, 80, 100
˚C) using a
thermostatically controlled water bath. Maximum absor-
bance values were obtained at room temperature.
Different types of surfactants, such as sodium lauryl
sulphate (anionic type), gelatin, and methyl cellulose
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Figure 5 Typical chromatograms showing ebastine alone and
after complexation. A. Typical chromatogram showing EBS-Zn
(ΙΙ) complex at 260 nm where: a) Solvent front b) Zn (ΙΙ) 0.0025%
c) Cetirizine hydrochloride internal standard (15 μg/ml). d) Ebastine-
Zn (ΙΙ) complex; (EBS = 4 μg/ml) B. A chromatogram showing
ebastine alone at 260 nm where: a) Solvent frontb) Zn (ΙΙ)
0.0025% c) Cetirizine hydrochloride internal standard (15 μg/ml). d)
Ebastine alone (4 μg/ml)
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Page 6 of 14(non ionic types) were added to the reaction mixture to
test their effect on the absorbance value of the formed
complex hoping that they may enhance the absorbance
readings, but it was found that all the studied surfac-
tants had no significant effect on the absorbance value
of the formed complex, hence the complex formation
was carried out without their addition. Similarly differ-
ent sensitizers were tested such as quinine, fluorescein
and rhodamine-B. Addition of sensitizers to the reaction
mixture was found to enhance the absorbance but with
the lack of reproducibility. Therefore, the study was car-
ried out without the addition of sensitizers.
The effect of ionic strength on the absorbance read-
ings was followed by adding different concentrations of
KCl (0.01- 0.1 M), which revealed that KCl did not have
any significant effect on the formation of the studied
complex.
The formation and stability of the formed complex
was also studied by measuring the absorbance readings
every 10 minutes interval, the consistency of the absor-
bance values indicated that EBS-Zn (ΙΙ) complex was
formed instantaneously and remained stable for at least
90 minutes.
Reaction stoichiometry
The stoichiometry of the reaction between EBS and Zn
(II) was determined spectrophotometrically by applying
Job’s continuous variation method [18], where the plot
reached a maximum value at a mole fraction of 0.6,
which indicated the formation of a 2:1 EBS : Zn (ΙΙ)
complex.
The formation constant of the reaction product was
calculated according to the following equation [19]:
Kf =
A/Am
[(1 − A/Am)n+1]cnnn
where A and Am are the observed maximum absor-
bance and the absorbance obtained from the extrapola-
tion of the two lines obtained from Job’s continuous
variation method, respectively; n is the number of moles
of Zn
2+ involved in the complex formation reaction ; n
= 1; C is the molar concentration of the drug used in
Job’s continuous variation method.
Using the above equation Kf was found to be 5.2 ×
10
5
Also, the Gibbs free energy changes (ΔG) of the reac-
tion were calculated according to the following equation
[19]:
G=−2.303 RT log Kf
Where R is gas constant = 8.3 joule.degree
-1.mole
-1;T
is temperature (K).
Using the above equation ΔG was found to be -2.4 ×
10
3 Joule/Mole.
The high negative value of ΔG indicates that the reac-
tion is spontaneous.
Chromatographic performances
A well-defined symmetrical peak was obtained upon
measuring the response of the eluent under the perfor-
mance parameters after thorough experimental trials
that could be summarized as follows:
Ratio of aqueous: organic phase
T h ee f f e c to fB r i t t o nR o b i n s o nb u f f e r :o r g a n i cp h a s e ;
(acetonitrile-methanol mixture) ratio on the separation
of the formed complex was studied. Satisfactory separa-
tion was obtained with a mobile phase consisting of
Britton Robinson bufferp H4 . 2 :o r g a n i cp h a s e
(35:65-
30:70 v/v) at ambient temperature. At lower organic
phase concentrations (< 65%); decrease in the number
of theoretical plates (NTP) and peak area ratios was
observed.
Ratio of acetonitrile: methanol in the organic phase
The influence of the ratio of acetonitrile: methanol in
the organic portion of the mobile phase was followed.
Adequate resolution without peak tailing and maximum
peak area ratios resulted when the organic phase was
composed of acetonitrile : methanol in a ratio of 1:4.
Effect of pH
The pH of the mobile phase was investigated through
p Hf r o m3t o6 .I tw a sf o u n dt h a tp r o p e rr e s o l u t i o n
with highest NTP and peak area ratios was achieved at
pH 4 - 4.5. When the pH was lower than 4, remarkable
decrease in NTP with slight reduction in peak area
ratios resulted, while at pH higher than 4.5, sharp
decrease in the latter two parameters occurred.
Effect of buffer type
Different buffers of the same pH (4.2) were also studied.
Phosphate and acetate buffer resulted in peaks lacking
symmetry and in lower values of NTP and peak area
ratios than those obtained by Britton Robinson buffer.
Effect of molar strength of Britton Robinson buffer
The effect of different molar strengths of Britton Robin-
son buffer (pH 4.2) over the range (0.0075-0.1 M) on the
separation of the formed complex was investigated. It
was found that (0.015-0.05 M) Britton Robinson buffer
gave the highest NTP and peak area ratios. A gradual
decrease in the previously mentioned parameters was
observed when the molar strength was either lower than
0.015 M or higher than 0.05 M. Furthermore, alteration
of the peak symmetry of the resultant complex was
remarkably observed at the higher molar strength.
Effect of Zn (ΙΙ) concentration
The presence of Zn (II) in the mobile phase was essen-
tial to prevent the hydrolysis of the formed complex. In
Ibrahim et al. Chemistry Central Journal 2011, 5:24
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Page 7 of 14the absence of Zn (II) in mobile phase a very small peak
area ratios was obtained, so a mobile phase containing
0.0025% of Zn (II) was chosen for good formation and
separation of the formed complex (Figure 6).
Effect of different types of columns
Different types of columns were tried to perform the
separation of EBS-Zn (ΙΙ) complex. Successful separation
process was achieved by the EC nucleosil C18-SN :
4115568 column; on the other hand, it was found that
upon using Hibar prepacked column RT-250-4-L-100-
RP8 distorted peaks were obtained, while Zorbax
® SB-
Phenyl column (250 mm × 4.6 mm id (5 mm) resulted
in well separated peaks but with longer retention times.
Effect of detector wavelength
The UV detector response of the complex was studied
from the range of 220-280 nm, and the best wavelength
was found to be 260 nm showing highest sensitivity and
appreciable absorbance of EBS-Zn (ΙΙ) complex.
Effect of flow rate
The effect of different flow rates (0.6-1.5 ml/min) on the
separation of the complex was tested, and it was found
that 1 ml/min was the most suitable flow rate regarding
the retention times and the symmetry of the peaks.
A collective study of experimental parameters affecting
the chromatographic separation is summarized in Table 1.
Analytical performance and applications
Validation of the method
By using the above liquid chromatographic method, lin-
ear regression equation was obtained. The regression
plot showed that, there was a linear dependence of the
peak area ratio on the concentration of the drug over
the working concentration range. The validity of the
proposed method was evaluated by statistical analysis of
the regression data (Table 2) regarding the standard
deviation of the residuals (Sy/x), the standard deviation
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Figure 6 Effect of concentration of Zn (ΙΙ) in the mobile phase
on the peak area ratios of the formed complex.
Table 1 Effect of experimental parameters on the
separation of EBS-Zn (ΙΙ) complex
Parameter K’ N HETP Rs Peak area
ratio
Buffer type and pH
Britton Robinson buffer
pH
3 3.41 1036 0.0145 2.73 0.726
3.5 3.92 1034 0.0145 3.58 0.743
4 5.53 2706 0.0055 5.012 0.784
4.5 5.13 2698 0.0055 5.012 0.784
5 3.84 1507 0.0099 4.177 0.752
5.5 3.66 769 0.0195 3.166 0.688
6 3.76 258 0.0581 3.133 0.564
Phosphate buffer pH 4.2 4.26 1479 0.0101 2.72 0.366
Acetate buffer pH 4.2 4.06 1027 0.0146 1.271 0.521
Ratio of aqueous: organic phase(acetonitril: methanol; 1:4)
45:55 4.02 837 0.0179 1.088 0.29
40:60 4.25 1034 0.0145 4.15 0.45
35:65 5.53 2706 0.0055 5.012 0.784
30:70 5.52 2687 0.0056 5.009 0.783
Ratio of acetonitril: methanol
1:4 5.53 2706 0.0055 5.012 0.784
2:3 3.52 1210 0.0124 3.64 0.645
3:2 2.73 2205 0.0068 4.45 0.429
4:1 4.103 1393 0.0108 4.41 0.235
Acetonitril only 5.08 1347 0.0111 4.745 0.198
Methanol only 4.938 1817 0.0083 4.371 0.349
Ionic strength of BRb (Molar)
0.0075 4.256 911 0.0165 3.714 0.48
0.01 5.23 1895 0.0079 4.015 0.69
0.015 5.53 2706 0.0055 5.012 0.784
0.02 5.52 2716 0.0053 5.009 0.782
0.05 5.55 2720 0.0052 5.011 0.783
0.07 4.62 1816 0.0083 4.127 0.642
0.1 4.67 1173 0.0128 4.143 0.513
Flow rate (mL/minute)
0.6 4.348 466 0.0322 2.11 0.92
0.7 4.291 1013 0.0148 2.64 0.84
0.8 4.342 1070 0.0141 2.69 0.75
1 5.53 2706 0.0055 5.012 0.784
1.1 5.26 1982 0.0076 4.857 0.662
1.2 4.74 1486 0.0101 4.33 0.679
1.3 4.25 1057 0.0142 3.21 0.54
1.4 4.12 1013 0.0148 2.94 0.49
1.5 3.97 925 0.0162 2.76 0.33
Where:
K’ is the capacity factor; K’=t R -t M/tM
N is the number of theoretical plates; N=
5.55t2
R
w2
1/2 HETP is the height equivalent to a theoretical plate; HETP = L/N
Rs is the resolution factor; Rs =
2[tR -t M]
wR +w M (tR is the retention time of the complex, tM is the time from injection to the
appearance of the solvent front, w1/2 is the peak width at half height, L is the
length of the column, wR and wM are the peak width at base line for the
complex and the solvent front respectively)
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Page 8 of 14of the intercept (Sa), and standard deviation of the slope
(Sb) [20]. The small values of the figures point to the
low scattering of the points around the calibration
graph and high precision of the proposed method
Linearity
The peak area ratio of EBS varied linearly with the con-
centration over the range 0.3-6 mg/ml as mentioned in
Table 2.
Linear regression analysis of the data gave the follow-
ing equation:
P = 0.1975 C + 4.78 × 10−4(r = 0.9999)
Where C is the concentration in mg/ml and P is the
peak area ratio.
Sensitivity
The calculated values of LOQ and LOD are listed in
Table 2.
The linear dependence of the peak area ratio versus
the concentration of the drug was shown by calculation
of the regression equation previously mentioned
Accuracy
Statistical analysis [20] of the results obtained by the
proposed and comparison methods using student’s t-test
and variance ratio F- test, showed no significant differ-
ence between the performance of the two methods
regarding the accuracy and precision, respectively (Table
3). The comparison method is based on an HPLC mea-
surement of EBS using a mobile phase consisting of
methanol: water (90:10, v/v/v) with UV detection at 262
nm.
Precision
Repeatability
The mean percentage recoveries based on the average of
four separate determinations for pure and dosage forms
are abridged in Table 4.
Intermediate precision
The percentage recoveries are based on the average of
four separate determinations. The results are shown in
Table 4.
Pharmaceutical applications
Dosage forms analysis
The proposed method was successfully applied to the
determination of EBS in its dosage forms. The average
percentages found of different concentrations were
based on the average of three replicate determinations.
The results shown in Table 5 are in good agreement
with the comparison method [4].
Content uniformity testing
Due to the high precision of the method, and its ability
to rapidly estimate the concentration of the drug in a
single tablet extract with sufficient accuracy, the method
is suited for content uniformity testing which is a time
Table 2 Performance data of the proposed method
Parameter Value
Concentration range (μg/ml) 0.3-6.0
LOD(μg/ml) 0.13
LOQ(μg/ml) 0.26
Correlation coefficient (r) 0.9999
Slope 0.1975
Intercept 4.78 × 10
-4
Sy/x , Standard deviation of the residuals 8.93 × 10
-4
Sa ,Standard deviation of the intercept of the regression line 7.49 × 10
-5
Sb ,Standard deviation of the slope of the regression line 1.49 × 10
-4
Table 3 Application of the proposed method for the analysis of ebastine in pure form
Proposed method Comparison method [4]
Amount taken (μg/ml) Amount found (μg/ml) % Recovery % Recovery
0.3 0.2976 99.21 100.62
0.5 0.5031 100.62 99.15
0.7 0.7030 100.43 99.34
1.0 0.9972 99.72
2.0 2.0148 100.74
3.0 3.0072 100.24
4.0 3.9912 99.78
5.0 4.981 99.62
6.0 6.0264 100.44
Xˉ ±S D 100.09 ± 0.52 99.70 ± 0.79
Student’s t test 0.61(1.86)*
Variance ratio F test 2.3(5.25)*
*Figures between parentheses are the tabulated t and F values at p = 0.05 [20].*
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Page 9 of 14Table 4 Validation of the proposed HPLC method for determination of ebastine in pure and dosage forms
Preparation Repeatability, % Recovery Intermediate precision, %Recovery
Ebastine pure form Ebastine (5.0 μg/ml) Ebastine (6.0 μg/ml)
99.95 100.95
100.25 100.38
100.54 99.65
100.87 99.12
Xˉ ± SD 100.41 ± 0.39 100.03 ± 0.81
Bastab
® tablets Ebastine (0.3 μg/ml) Ebastine (4.0 μg/ml)
99.65 99.35
99.84 99.98
100.58 100.87
100.68 100.92
Xˉ ± SD 100.19 ± 0.52 100.28 ± 0.76
Evastine
®syrup Ebastine (2.0 μg/ml) Ebastine (3.0 μg/ml)
100.14 99.32
100.55 100.84
100.92 100.99
99.64 100.06
Xˉ ± SD 100.31 ± 0.55 100.31 ± 0.77
Table 5 Determination of ebastine in its dosage forms by the proposed HPLC method
Proposed method Comparison method [4]
Preparation Amount taken (μg/ml) Amount found (μg/ml) % Recovery % Recovery
Bastab
® tablets 0.3 0.2974 99.14 99.23
0.7 0.6981 99.72 99.61
1.0 1.0094 100.94 100.61
3.0 3.0036 100.12
5.0 4.9835 99.67
6.0 5.9844 99.74
Xˉ ±S D 99.88 ± 0.61 99.82 ± 0.71
Student’s t test 0.39(2.02)*
Variance ratio F test 1.35(3.78)*
Evastine
® syrup 0.3 0.30216 100.72 100.12
0.7 0.69615 99.45 99.61
1.0 1.0011 100.11 99.51
3.0 3.0144 100.48
5.0 5.031 100.62
6.0 5.9994 99.99
Xˉ ±S D 100.23 ± 0.48 99.75 ± 0.33
Student’s t test 0.23(2.02)*
Variance ratio F test 2.12(3.78)*
*Figures between parentheses are the tabulated t and F values at p = 0.05 [20].*
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Page 10 of 14consuming process when using conventional assay tech-
nique. The steps of the test were adopted according to
the United States Pharmacopoeia [17] procedure. The
acceptance value AV was calculated for each of the
commercially available tablets and it was found to be
smaller than the maximum allowed acceptance value L1.
The results demonstrated reasonable drug uniformity as
shown in Table 6.
Interferences
Many drugs which are frequently co- administered with
EBS such as erythromycin and ketoconazole were care-
fully tested. The studied drugs were found to be ade-
quately separated from the formed complex (Figures 7
a, b).
Forced degradation studies of EBS
In order to establish whether the analytical method was
stability indicating, EBS was stressed under various con-
ditions to contact forced degradation studies [16].
Methanol was used as a co-solvent in all forced degrada-
tion studies.
Degradation kinetics study
For the kinetic study, 2 M sodium hydroxide was used
for alkaline degradation of the drug. Regarding the UV
degradation, the methanolic solution of EBS was
exposed to Deuterium lamp in a wooden cabinet dis-
tance of 15 cm for different time intervals.
The apparent decrease in the peak area ratios of EBS
upon alkaline degradation with 2M sodium hydroxide in
a boiling water bath, and under UV lamp at different
time intervals are demonstrated in Figures 8 (Ι-ΙV) and
9( Ι-ΙV).
The degradation was found to be temperature depen-
dant (Figures 10 and 11). Regarding the alkaline
Table 6 Content uniformity testing of ebastine in its
dosage forms using the proposed method
Parameter Percentage of the label claim
Data Bastab
® tablets Ebastel
® tablets
100.25 100.67
101.12 99.64
100.65 99.18
99.81 100.66
99.54 100.82
100.91 101.11
99.34 99.37
100.55 99.42
101.18 100.68
99.45 99.35
Mean Xˉ 100.28 100.09
SD 0.704 0.754
%Error 0.22 0.24
Acceptance value (AV) 1.69 1.81
Maximum allowed value (L1) 15.00
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Figure 7 Typical chromatograms of EBS-Zn
2+ complex in
presence of co-administered drugs. A. Typical chromatogram
showing EBS-Zn (ΙΙ) complex in presence of erythromycin
where: a) Solvent front b) Zn (ΙΙ) 0.0025% c) Cetirizine hydrochloride
internal standard (15 μg/ml). d) Ebastine - Zn (ΙΙ) complex; (EBS = 4
μg/ml) e) Erythromycin (20 μg/ml) B. Typical chromatogram
showing EBS-Zn (ΙΙ) complex in presence of ketoconazole
where: a) Solvent front b) Zn (ΙΙ) 0.0025% c) Cetirizine hydrochloride
internal standard (15 μg/ml). d) Ebastine - Zn (ΙΙ) complex; (EBS = 4
μg/ml) e) Ketoconazole (20 μg/ml)
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Figure 8 (Ι-ΙV) Typical chromatograms showing the decrease in
peak area ratios of EBS- Zn (ΙΙ) complex by alkaline
degradation at different time intervals where: a) Solvent front b)
Zn (ΙΙ) 0.0025% c) Cetirizine hydrochloride internal standard (15 μg/
ml). d) Ebastine- Zn (ΙΙ) complex
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Figure 9 (Ι-ΙV) Typical chromatograms showing the decrease in
peak area ratios of EBS- Zn (ΙΙ) complex by UVdegradation at
different time intervals where: a) Solvent front b) Zn (ΙΙ) 0.0025%
c) Cetirizine hydrochloride internal standard (15 μg/ml). d) Ebastine-
Zn (ΙΙ) complex
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Page 12 of 14degradation, the first order degradation rate constant
and the half life time at each temperature were calcu-
lated (Table 7) according to the following equations:
ln a/a-x = Kt where a is the initial concentration of
the drug, × is the concentration of the resulting
degraded solution after time t, and K is the reaction rate
constant
While the half life time could be calculated as follows:
t1/2 = 0.693/K.
Plotting log Kobs values versus 1/T, the Arhenius plot
was obtained (Figure 12). The activation energy was also
calculated by the equation:
ln K = - Ea/RT+ ln A where: Ea is the activation
energy, K is first order reaction rate constant, R is the
gas constant, and T is the temperature in kelvin.
On the other hand, the proposed method did not indi-
cate either the acidic or the oxidative degradation of
ebastine. In both cases, the peak corresponding for the
complex did not appear in the chromatogram, pointing
out that the degradation step altered the chemical moi-
ety responsible for the complexation between EBS and
Zn (ΙΙ). The acidic degradation is supposed to act on
the basic centre of the studied drug; teriary amine,
which is involved in the complex formation, and hence,
the complex will be no further be formed. While, the
oxidative degradation carried out with 6% hydrogen per-
oxide may cause the oxidation of the tertiary amino
group to the N-oxide derivative, and subsequently alter
the complex formation.
Conclusion
A simple, sensitive and rapid HPLC method has been
developed for the determination of ebastine in its
pharmaceuticals. The sensitivity of the proposed
method allows its application for content uniformity
testing. Extensive study concerning the composition
and stability of the complex was also conducted.
Another advantage of the studied method is its stabi-
lity indicating property which was utilized to investi-
gate the kinetics of alkaline and ultraviolet induced
degradation of the drug. Validation was carefully stu-
died to elicit an assay which can be used in routine
quality control laboratories.
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Figure 10 Semilogarithmic plot of EBS (4 μg/ml) versus
different heating times with 2M NaOH. (A = 80°C, B = 70 °C, C =
60 °C, and D = 50 °C).
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Figure 11 Semilogarithmic plot of EBS (4 μg/ml) versus
different times under UV lamp.
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Figure 12 Arrhenius plot for the degradation of EBS (4 μg/ml)
in 2 M NaOH.
Table 7 Effect of temperature on the kinetic parameters
of EBS
Temperature (°C) K (min.
-1)t 1/2 (min.)
50 0.001137 609
60 0.00134 517
70 0.001515 421
80 0.001691 410
Ea = (K.Cal.mol
-1) 7.3
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